Akèy › Kansè Metastatik › Massachusetts › Boston
Etid klinik pou Kansè Metastatik nan Boston, MA
63 etid pou Kansè Metastatik ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
Ap rekriteFaz 1
- Dana-Farber Cancer Institute, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- Dana Farber Cancer Institute, Boston
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
A Study of ASP3082 in Adults With Advanced Solid Tumors
Ap rekriteFaz 1
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Ap rekriteFaz 2/3
- Dana-Farber Cancer Institute, Boston
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Ap rekriteFaz 3
- Brigham and Women's Hospital (BWH), Boston
- Dana-Farber Cancer Institute (DFCI), Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute., Boston
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Ap rekriteFaz 1/2
- Mass General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Ap rekriteFaz 1
- Mass General Cancer Center, Boston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Ap rekriteFaz 3
- Massachusetts General Hospital, Boston
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Ap rekriteFaz 3
- Mass General Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Ap rekriteFaz 1/2
- Massachusetts General Hospital - Main Campus, Boston
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Ap rekriteFaz 1/2
- Brigham and Women's Hospital, Boston
- Dana Farber/Mass General Brigham Cancer Care, Inc, Boston
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
Ap rekriteFaz 1
- Dana-Farber Cancer Institute, Boston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Boston Medical Center, Boston
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Ap rekriteFaz 2
- Dana-Farber Cancer Institute, Boston
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, Boston
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital (MG), Boston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- Dana-Farber Cancer Institute, Boston
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, Boston
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
Ap rekriteFaz 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
Ap rekriteFaz 1
- Dana-Farber Cancer Institute, Boston
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Ap rekriteFaz 1
- Dana-Farber Cancer Institute, Boston
A Study of PYX-201 in Advanced Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Ap rekriteFaz 1
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #10, Boston
- Exelixis Clinical Site #11, Boston
A Study of LY4175408 in Participants With Advanced Cancer
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Research Site, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Ap rekriteFaz 1
- Research Site, Boston
- Research Site, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Ap rekriteFaz 3
- Massachusetts General Hospital Cancer Center, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Ap rekriteFaz 2
- I-Mab Site 1002, Boston
Remote Monitoring and Symptom Management Digital Application
Ap rekrite
- Massachusetts General Hospital, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Ap rekriteFaz 2/3
- Dana-Farber Cancer Institute, Boston
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 3
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Ap rekriteFaz 2/3
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Ap rekriteFaz 2/3
- Massachusetts General Hospital, Boston
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Ap rekriteFaz 1/2
- Dana-Farber Cancer Institute, Boston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Ap rekriteFaz 1/2
- Dana-Farber Cancer Institute, Boston
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Ap rekriteFaz 1
- Dana-Farber Cancer Institute, Boston
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
Ap rekrite
- Massachusetts General Hospital, Boston
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Mass General Hospital, Boston
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Ap rekriteFaz 3
- Dana-Farber Cancer Institute, Boston
IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pelvis Fractures
Ap rekriteEtid obsèvasyon
- Massachusetts General Hospital, Boston
Comprehensive Outcomes for After Cancer Health
Ap rekriteVolontè an sante akeyi
- Dana Farber Cancer Institute, Boston
Etid Kansè Metastatik nan lòt vil
- Houston, TX104 etid
- New York City, NY93 etid
- Nashville, TN70 etid
- Los Angeles, CA57 etid
- St. Louis, MO54 etid
- Arlington, VA53 etid
- Philadelphia, PA46 etid
- Chicago, IL45 etid
- San Antonio, TX44 etid
- Washington, DC43 etid
- Dallas, TX42 etid
- Seattle, WA39 etid
Lòt etid nan Boston
- Kansè nan tete111 etid
- Kansè Poumon ki pa ti selil90 etid
- Kansè (tout kalite)86 etid
- Kansè kolorektal63 etid
- Kansè poumon62 etid
- Kansè ovè61 etid
- Kansè pwostat59 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Ensifizyans kadyak44 etid
- Leksemi mieloïd egi44 etid
- Kansè pankreyas43 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.